Anti-VEGF antibodies like bevacizumab enhance the effectiveness of PD-1/PD-L1 inhibitors in hepatocellular carcinoma (HCC) through multiple mechanisms. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.